Advertisement

Lymphoma Medications

Here's a list of the approved drugs to treat lyphoma, including non-Hodgkin and Hodgkin lymphoma. Click on any of the medications for more info on indications, dosing and side effects.


Quick Filter

*generic version available

E experimental

DRUG Chemotherapy
GENERIC NAME Multiple
DRUG INDICATION

Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.

DRUG Arranon
GENERIC NAME nelarabine
DRUG INDICATION

Arranon is a nucleoside inhibitor approved for refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

DRUG Beleodaq
GENERIC NAME belinostat
DRUG INDICATION

Beleodaq is an HDAC inhibitor approved for relapsed or refractory peripheral T-cell lymphoma.

DRUG Istodax
GENERIC NAME romidepsin
DRUG INDICATION

Istodax is an HDAC inhibitor approved for previously treated cutaneous and peripheral T-cell lymphoma.

DRUG Xpovio
GENERIC NAME selinexor
DRUG INDICATION

Xpovio is the first approved nuclear export inhibitor. It is indicated for the treatment of people with relapsed or refractory (nonresponsive) multiple myeloma or diffuse large B-cell lymphoma.

DRUG Zolinza
GENERIC NAME vorinostat
DRUG INDICATION

Zolinza is an HDAC inhibitor approved for people with cutaneous T-cell lymphoma that does not respond to other systemic therapy.

 

DRUG Keytruda
GENERIC NAME pembrolizumab
DRUG INDICATION

Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, relapsed or refractory classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma and cutaneous squamous cell carcinoma. It is also approved for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency mutations (MSI-H/dMMR) or high tumor mutation burden. 

DRUG Kymriah
GENERIC NAME tisagenlecleucel
DRUG INDICATION

Kymriah is a CAR-T therapy approved for relapsed or refractory B-cell acute lymphoblastic leukemia in children and young adults up to age 25 and for relapsed or refractory diffuse large B-cell lymphoma in adults.

DRUG Opdivo
GENERIC NAME nivolumab
DRUG INDICATION

Opdivo is a checkpoint inhibitor approved for inoperable or metastatic melanoma, metastatic or recurrent non-small-cell lung cancer, metastatic small-cell lung cancer, advanced kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, advanced or metastatic bladder (urothelial) cancer, liver cancer, recurrent or metastatic esophageal cancer and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations. 

DRUG Revlimid
GENERIC NAME lenalidomide
DRUG INDICATION

Revlimid is an immunomodulator approved for multiple myeloma in combination with dexamethasone, for follicular lymphoma and marginal zone lymphomain in combination with Rituxan (rituximab),

and as a single drug for myelodysplastic syndromes and mantle cell lymphoma.

DRUG Tecartus
GENERIC NAME brexucabtagene autoleucel
DRUG INDICATION

Tecartus is a CAR-T therapy approved for adults with mantle cell lymphoma who have not responded to or who have relapsed after other kinds of treatment.

DRUG Yescarta
GENERIC NAME axicabtagene ciloleucel
DRUG INDICATION

Yescarta is a CAR-T therapy approved for relapsed or refractory large B-cell lymphoma (type of non-Hodgkin lymphoma) in adults, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma and DLBCL arising from follicular lymphoma.

DRUG Adcetris
GENERIC NAME brentuximab vedotin
DRUG INDICATION

Adcetris is a CD30-directed antibody-drug conjugate approved for anaplastic large cell lymphoma, classical Hodgkin lymphoma and peripheral T-cell lymphoma.

 

DRUG Aliqopa
GENERIC NAME copanlisib
DRUG INDICATION

Aliqopa is a PI3K kinase inhibitor approved for relapsed follicular lymphoma.

DRUG Arzerra
GENERIC NAME ofatumumab
DRUG INDICATION

Arzerra is a monoclonal antibody approved for chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, alone or in combination with chemotherapy.

DRUG Brukinsa
GENERIC NAME zanubrutinib
DRUG INDICATION

Brukinsa is a BTK kinase inhibitor approved the previously treated adults with mantle cell lymphoma.

DRUG Calquence
GENERIC NAME acalabrutinib
DRUG INDICATION

Calquence is a BTK kinase inhibitor approved for mantle cell lymphoma and as a first-line or subsequent treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

DRUG Copiktra
GENERIC NAME duvelisib
DRUG INDICATION

Copiktra is a PI3K kinase inhibitor approved for relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma.

DRUG Gazyva
GENERIC NAME obinutuzumab
DRUG INDICATION

Gazyva is a monoclonal antibody approved for follicular lymphoma and chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, in combination with chemotherapy.

DRUG Imbruvica
GENERIC NAME ibrutinib
DRUG INDICATION

Imbruvica is a BTK kinase inhibitor approved for mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, marginal zone lymphoma and Waldenstrom macroglobulinemia.

DRUG Monjuvi
GENERIC NAME tafasitamab
DRUG INDICATION

Monjuvi is a CD19-directed monoclonal antibody approved for the treatment of relapsed or refractory (nonresponsive) diffuse large B-cell lymphoma in combination with Revlimid (lenalidomide).

DRUG Polivy
GENERIC NAME polatuzumab vedotin-piiq
DRUG INDICATION

Polivy is a CD79b-directed antibody-drug conjugate approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine and a rituximab product such as Rituxan.

DRUG Rituxan
GENERIC NAME rituxumab
DRUG INDICATION

Rituxan is a monoclonal antibody approved for follicular lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, alone or in combination with chemotherapy. Truxima and Ruxience are biosimilar medications.

DRUG Tazverik
GENERIC NAME tazemetostat
DRUG INDICATION

Tazverik is an EZH2 methyltransferase inhibitor approved for the treatment of inoperable epithelioid sarcoma (a type of soft tissue cancer) and for relapsed or refractory follicular lymphoma.

DRUG Velcade
GENERIC NAME bortezomib
DRUG INDICATION

Velcade is a proteasome inhibitor approved for multiple myeloma and mantle cell lymphoma.

DRUG Zydelig
GENERIC NAME idelalisib
DRUG INDICATION

Zydelig is a PI3K kinase inhibitor approved for relapsed follicular lymphoma, relapsed chronic lymphocytic leukemia and relapsed small lymphocytic lymphoma.


Advertisement